select search filters
briefings
roundups & rapid reactions
before the headlines
Fiona fox's blog
Today Novavax have announced the results of their PREVENT-19 Phase 3 Trial which looks at the overall efficacy and protection against moderate and severe disease of the Novavax COVID-19 vaccine.
The Novavax president of R&D was available to give a briefing summary of the data to journalists and answer any of their questions.
Speakers included:
Dr Gregory Glenn, MD, President of R&D, Novavax
This Briefing was accompanied by an SMC Roundup of Comments.